Introduction
Both types of sleep-disordered breathing (SDB), obstructive and central sleep apnoea (OSA and CSA, respectively), are common in patients with heart failure and reduced ejection fraction (HFrEF). In such patients, SDB is associated with increased cardiovascular morbidity and mortality but it remains uncertain whether treating SDB by adaptive servo-ventilation (ASV) in such patients reduces morbidity and mortality. 
Methods
ADVENT-HF is a multicentre, multinational, randomized, parallel-group, open-label trial with blinded assessment of endpoints of standard medical therapy for HFrEF alone vs. with the addition of ASV in patients with HFrEF and SDB. Patients with a history of HFrEF undergo echocardiography and polysomnography. Those with a left ventricular ejection fraction ≤45% and SDB (apnoea-hypopnoea index ≥15) are eligible. SDB is stratified into OSA with ≥50% of events obstructive or CSA with >50% of events central. Those with OSA must not have excessive daytime sleepiness (Epworth score of ≤10). Patients are then randomized to receive or not receive ASV. The primary
Introduction
Despite advances in therapy, morbidity and mortality from heart failure (HF) with reduced ejection fraction (HFrEF) remain high.
1 To reduce this burden, it is necessary to identify potentially treatable conditions contributing to its progression. One such condition, sleep-disordered breathing (SDB), is present in approximately 50% of patients with HFrEF, 2 -6 and increases mortality independently of other risk factors. 7 -11 SDB in patients with HF may manifest as either obstructive sleep apnoea (OSA) or central sleep apnoea (CSA), and both these types of SDB may be seen in an individual patient on the same night, 12 or the predominant type of SDB can shift from CSA to OSA or vice versa over time in relation to worsening or improving cardiac function, respectively.
13,14
Obstructive sleep apnoea and heart failure Over time, OSA can increase the risk of developing hypertension, LV hypertrophy, progression of HFrEF, cardiac arrhythmias, and stroke.
15 -17 Several small short-term randomized clinical trials (RCTs) in HF patients with OSA demonstrated that treatment of OSA with continuous positive airway pressure (CPAP) improved LV ejection fraction (LVEF), 18 -21 and reduced daytime sympathetic activity and the frequency of nocturnal ventricular ectopy. 22, 23 However, compared to the general population with OSA, HFrEF patients with OSA have less subjective daytime sleepiness, assessed by the Epworth Sleepiness Scale (ESS), and hence lack the usual indication of hyper-somnolence to treat OSA. 18, 24, 25 Studies have shown that treating moderate to severe OSA in patients without HF and excessive daytime sleepiness had no effect on objective or subjective sleepiness, health-related quality of life, neurocognitive function, performance on a driving simulator, or blood pressure. 26, 27 Furthermore, two RCTs involving non-sleepy patients with moderate to severe OSA, one in patients with, and one in patients without, coronary artery disease, also demonstrated no effect of treating OSA with CPAP on morbidity or mortality. 28, 29 Consequently, most HF patients with OSA would not have a clear indication for treatment of their OSA. trial, showed that treating CSA by CPAP for a mean of 2 years attenuated CSA, improved nocturnal oxygenation, LVEF, and 6 min walking distance, but did not affect heart transplant-free survival. 31 However, 3 months post-randomization, CPAP failed to suppress the apnoea-hypopnoea index (AHI) to below the trial entry threshold of 15 in 43% of patients. In a post hoc analysis in which heart transplant-free survival was compared between patients randomized to CPAP in whom the AHI was reduced to below 15 3 months post-randomization (CSA-suppressed), and the control group, 32 the CSA-suppressed group had significantly higher transplant-free survival [hazard ratio (95% confidence interval) = 0.36 (0.14-0.95), P = 0.040]. In contrast, among those in whom CPAP did not reduce the AHI to below 15, heart transplant-free survival tended to be worse than in the control group. These observations suggested that early suppression of CSA by CPAP is an important therapeutic goal that could lead to improved outcomes. Thus, a device such as adaptive servo-ventilation (ASV) that more effectively suppresses CSA than CPAP might have greater potential to reduce morbidity and mortality in patients with HFrEF.
Central sleep apnoea and heart failure

Adaptive servo-ventilation
ASV is a positive airway pressure device designed specifically to eliminate CSA in HFrEF patients. In small RCTs, ASV was more effective in suppressing CSA than oxygen, CPAP or bi-level positive airway pressure. 33, 34 The ASV device that we have employed in ADVENT-HF (Philips Respironics BiPAP AutoSV Advanced System One) uses peak flow to trigger pressure support (peak flow-triggered ASV or ASVpf) and has relatively low default pressures [minimum expiratory positive airway pressure (EPAP) of 4 cmH 2 O and minimum inspiratory pressure support of 0 cmH 2 O]. 35 When this ASVpf device detects a central apnoea or hypopnoea it delivers inspiratory pressure support automatically to generate peak airflow at approximately 90% of the patient's own mean level, so as not to induce hyperventilation. When this device detects that the patient is generating adequate airflow, the ASVpf reduces pressure support to as low as 0 cmH 2 O to prevent excessive ventilation. The device also automatically titrates EPAP to eliminate obstructive apnoeas and hypopnoeas. 36 Since in patients with HF, SDB can transform from central to obstructive, and vice versa, ASVpf can adapt to eliminate either of these respiratory events more effectively than CPAP. 
Methods
Study design
Subjects
Stable outpatients with a history of HFrEF (LVEF ≤ 45%) of at least 3 month duration and SDB are eligible if they meet the inclusion and exclusion criteria listed in Tables 1 and 2 . Sleep apnoea is defined as an AHI ≥ 15, and is divided into predominantly OSA (≥50% of events obstructive), or predominantly CSA (>50% of events central). 4, 10, 31, 37 A further requirement for patients with OSA is an ESS score of ≤10 and no or mild daytime sleepiness. 38 For patients with CSA, no ESS or subjective sleepiness criteria will be used, since there is very little evidence that CSA is associated with hypersomnolence, or that treating CSA reduces sleepiness.
Protocol Screening
After providing signed consent, subjects undergo a screening visit to document age, sex, height, weight, body mass index, medical history, aetiology and time of diagnosis of HFrEF, medications, physical examination including sitting blood pressure and heart rate, height and weight, American Heart Association (AHA)/American College of Cardiology (ACC) Stages of HF 1 , New York Heart Association (NYHA) classification, and a 12-lead electrocardiogram (ECG). A venous blood sample is drawn from which plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration is assessed. Functional capacity, quality of life, and sleepiness are assessed by 6 min walk test, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), 39 and the ESS, respectively. Subjects then undergo an echocardiographic examination, and for those who have not had a polysomnogram (PSG) meeting study standards within the previous 3 months, a PSG. At the time of enrolment, all subjects must be on optimal standard therapy for HFrEF, conforming to contemporary guidelines such as the Canadian Cardiovascular Society guidelines, 40 the recently updated AHA 41 and European Society of Cardiology guidelines 42 or those of the relevant country. All cardiac medications must remain unchanged for at least 2 weeks before randomization, and any beta-blocker must have been initiated at least 3 months prior to randomization. Subjects are not to be recruited during hospitalization. 
Echocardiography
Echocardiography is performed by qualified sonographers or cardiologists, blinded to treatment allocation. Each study includes M-mode and 2-D images obtained from the standard parasternal and apical windows. Biplane Simpson's method 43 is used for measurement of LV end-diastolic and end-systolic volumes from which LVEF is derived. Prior to site initiation, all site echocardiography laboratories are certified by the Core Echocardiography Laboratory at the Toronto General Hospital where all subsequent echocardiograms are sent via CD stored in Digital Imaging and Communications in Medicine (DICOM) format for analysis and interpretation.
Polysomnography
Eligible patients undergo an overnight PSG in a sleep laboratory with a technologist in attendance throughout the study. Prior to site initiation, PSGs from all site sleep laboratories are certified by the Core Sleep Laboratory at the Toronto Rehabilitation Institute where all subsequent PSGs are sent via the internet and stored in a central server for subsequent analysis and interpretation. Scoring of sleep stages and arousals from sleep are performed according to standard criteria. 31, 44, 45 Respiratory movements of the rib cage and abdomen are assessed by respiratory inductance plethysmography. 46 Intranasal pressure is also monitored as an index of airflow. 31, 47, 48 The ECG is monitored from a single precordial lead. Arterial oxy-haemoglobin saturation (SaO 2 ) is measured by pulse oximetry. Obstructive and central apnoeas and hypopnoeas are defined as previously described.
18,31 An O 2 desaturation index is quantified as the number of dips in SaO 2 of ≥3% per hour of sleep.
A follow-up PSG is performed 1 month after randomization in both the control and ASV-randomized subjects. Those allocated to ASV wear this device during the PSG and have its setting adjusted if necessary to control SDB.
Randomization
After a medical and medication stabilization period of 2 weeks, eligible subjects are randomly allocated to either standard optimal treatment for HFrEF alone or with the addition of ASV using an internet-based randomization system (Randomize.net).
Adaptive servo-ventilation titration
Subjects randomized to ASV have this initiated within 72 h during a second PSG. Initiation with a nasal mask is mandatory unless the subject is unable to tolerate it, in which case other interfaces may be used. Once the mask is placed and adjusted to minimize leaks, the PSG is commenced with the application of ASV programmed at the recommended starting pressures and settings ( Table 3 ). The sleep technologist may adjust pressures and back-up rate to minimize the AHI.
Following titration, the effective pressure and back-up rate settings are programmed into the subject's ASV device. All ASV titrations are transmitted via the internet to the Core Sleep Laboratory where they are scored and interpreted. The interpretation along with the recommended ASV settings are then transmitted back to the trial site.
Follow-up
The study schedule for participants is illustrated in Figure 1 . Following randomization, patients attend a clinic visit after 1 month, 3 months, 6 months, and every 6 months thereafter, up to a maximum of 5 years.
Table 1 Inclusion criteria
Male or female ≥ 18 years Documented American Heart Association Stages B, C, and D HFrEF due to ischaemic, idiopathic or hypertensive causes for at least 3 months Left ventricular ejection fraction ≤ 45%, as determined by echocardiography at screening On optimal medical therapy conforming to contemporary national or American Heart Association guidelines, 1 as determined by the patient's primary cardiologist No changes in cardiac medications during 2 weeks prior to randomization; if the patient is on a beta-blocker, beta-blocker therapy must have been started at least 3 months prior to randomization SDB with an AHI ≥ 15 events/h, which will be divided into OSA (≥50% of events obstructive), or CSA (>50% of events central in nature).
Subjects with OSA must also have an ESS score ≤10 and no or mild daytime sleepiness (by the International Classification of Sleep Disorders: occasionally falling asleep during passive situations is considered mild and not pathological). 34 CSA, central sleep apnoea; AHI, apnoea-hypopnoea index; ESS, Epworth Sleepiness Scale; HFrEF, heart failure with reduced ejection fraction; OSA, obstructive sleep apnoea; SDB, sleep-disordered breathing.
Table 2 Exclusion criteria
HFrEF due to primary valvular heart disease Hypertrophic obstructive, or restrictive, or post-partum cardiomyopathy Exercise capacity limited by class IV angina pectoris Acute myocardial infarction, cardiac surgery, percutaneous coronary intervention, ICD (if implanted for pacing function or secondary prevention), or CRT during the 3 months preceding randomization; only a 2 week waiting period before randomization is required if the ICD is implanted for primary prevention Active myocarditis Planned ICD or CRT Presence of left ventricular assist device Transplanted heart or expected to receive a transplanted heart within 6 months Pregnancy Current therapy of sleep apnoea including use of ASV, BiPAP, CPAP, mandibular advancement device, or treatment with any investigational sleep apnoea therapy during the last 4 weeks A clinical history of diseases other than HFrEF that would interfere with the objectives of this study or that would in the investigator's opinion reduce 5 year life expectancy Any other medical, social, or geographical factor that would make it unlikely that the patient will comply with the study procedures ASV, adaptive servo-ventilation; BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CRT, cardiac resynchronization therapy; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator. At the 1 month visit, all subjects undergo a follow-up PSG, with those on ASV wearing the device, and at the 6 month visit, a follow-up echocardiogram and NT-proBNP, and 6 min walking test assessment. Subjects remain in the study for a maximum of 5 years, at which point they undergo an end-of-study clinic visit during which assessments performed at routine half-yearly clinic visits are replicated.
Between planned visits, an extra clinic visit is required when: (i) the patient reports an adverse event that in the investigator's opinion warrants further assessment, (ii) the patient reports difficulties with . An ASV re-titration PSG is required among those with CSA if at the 1 month follow-up PSG the subject's AHI remains >15. If during the ASV re-titration PSG the AHI is still >15, then ASV is withdrawn. ASV re-titration is also required in subjects with either OSA or CSA if adherence is poor (defined as usage less than 50% of their baseline total sleep time per day) and the estimated leak is within acceptable limits and/or if a major complaint is pressure intolerance.
Outcomes
The primary study endpoint is the cumulative incidence rate of the composite of all-cause mortality, first hospitalization for cardiovascular (CV) diseases, new-onset atrial fibrillation/flutter requiring anticoagulation but not hospitalization, and delivery of an appropriate discharge from an implantable cardioverter-defibrillator (ICD) not resulting in hospitalization. Secondary endpoints include: (i) cumulative incidence rate of all-cause mortality, (ii) cumulative incidence rate of all CV hospitalizations, new-onset atrial fibrillation/flutter requiring anticoagulation but not hospitalization, or delivery of an appropriate discharge from an ICD not resulting in hospitalization, (iii) number 
Safety and efficacy
An independent data and safety monitoring committee (DSMC) has been established comprising three clinical trial experts, supported by an independent statistician, who function at arm's length from the trial investigators and from Philips Respironics. The DSMC conducts routine reviews of accumulating trial data every 6 months to ensure safety of the trial subjects.
Statistical analysis Sample size estimation
In the CANPAP study, the control-group rate for the composite outcome of death, heart transplant, or first CV hospitalization was 0. 35 
70% were CV hospitalizations)
. 31 From the CANPAP study patients in whom CSA was suppressed by CPAP, there was an estimated treatment effect (i.e. hazard ratio) of 0.8. 32 In an observational study in patients with OSA but without HF, Buchner et al. 49 found a hazard ratio of 0.36 for treatment of OSA for the outcome of fatal or non-fatal CV events. In a randomized controlled trial, one would expect a smaller effect; therefore, for this trial, the estimated hazard ratio for ASV-treated patients with OSA is more conservatively estimated to be 0.75. Thus, for the combined OSA and CSA groups the estimated hazard ratio is 0.775. It is estimated that 540 primary endpoints will be required to detect a between-group difference.
Allowing for a dropout rate of 2% per year and a rate of crossing over from treatment to control of 2% per year, and an overall type I error rate of 0.05, a total of 860 patients (430 OSA and 430 CSA) gives 82% power for the test of the treatment effect in a Cox proportional hazards analysis. If the control-group event rate in the OSA group is 20% lower, at 0.3 events per year, this sample size still provides 79% power.
Data analysis
The intention-to-treat analysis population will consist of all subjects who have been correctly randomized and will be used as the primary population to evaluate the study. Patients wrongfully randomized will be excluded from all study analyses. A per-protocol analysis will be performed as a sensitivity analysis. The per-protocol analysis population will consist of those randomized subjects: (i) who are randomized to ASV and demonstrate adequate adherence to it, defined as usage of at least 50% of the baseline total sleep time per night during the course of the trial, or (ii) who are randomized to the control arm and whose SDB is not specifically treated during the course of the trial. Those assigned to ASV who discontinue ASV will be excluded from the per-protocol analysis at the time they discontinue ASV. Those assigned to control who cross-over to receive SDB therapy will be excluded from the per-protocol analysis at the time of the cross-over.
The primary analysis will compare time to the occurrence of the first primary event between the ASV and control groups using a Cox proportional hazards model, with stratification according to sleep apnoea type (OSA and CSA), study centre and country. Death as a primary event will be one that occurs outside the hospital or during a first hospitalization.
Time to the first occurrence of each of the components of the primary composite outcome will be analyzed using the Cox model. The methods of Cook and Lawless 50 will be used to handle repeated hospitalizations and delivery of an appropriate shock from an ICD not resulting in hospitalization in patients who may or may not also have a terminal event. The number of days alive, not hospitalized will be compared using a randomization test. Cardiac resynchronization therapy and ICD implantation rates will be assessed using the time to first implantation.
Two interim analyses are planned after 50% (n = 270) and 75% (n = 405) of primary events have occurred. The DSMC can recommend stopping the trial prematurely if the nominal two-sided P-value between the groups at the first interim analysis is <0.0031, and at second interim analysis is <0.018 for the primary event rate. If following this review the DSMC recommends continuing the trial, they may recommend to the Steering Committee that a centre should not enrol additional patients, or that the protocol should be modified.
Project governance and administration
The trial executive, based at the Global Coordinating Centre at the University Health Network Toronto Rehabilitation Institute, will be responsible for overall project management. The names of committee members are provided in Appendix 1. All the participating sites and investigators are listed in Appendix 2.
Progress
The first study participant was enroled on 22 September 2010. As of the date of writing the number of active trial sites has increased from 30 at the outset of the trial to 41 sites in nine countries with 417 subjects enroled.
Discussion
Approximately 50% of patients with HFrEF have SDB that is associated with increased risk of mortality compared to patients without SDB. 7, 9, 51 In short-term small-scale randomized trials, treatment of OSA in HFrEF patients with CPAP improved cardiovascular function. 22, 24, 27 In an observational study involving HFrEF . patients, either with or without OSA, those with untreated OSA had higher mortality than those with no sleep apnoea. 10 There was also a non-significant tendency for patients with OSA treated with CPAP to have lower mortality than those whose OSA remained untreated. Nevertheless, because of the non-randomized observational nature of that study, one cannot conclude that treating OSA in HFrEF patients with positive airway pressure reduces morbidity or mortality.
At present, OSA appears more prevalent than CSA in HFrEF patients. In one study involving 218 stable outpatients with HFrEF receiving optimal contemporary therapy, the prevalence of OSA with an AHI ≥ 15 was 26%, whereas that of CSA was 21%. 51 In another study, Ferrier et al. also found a higher prevalence of OSA (53%) than CSA (15%) in stable HF patients. 2 These data indicate that a large proportion of HFrEF patients have OSA. Nevertheless, in a study of 30 719 patients covered by Medicare who were admitted to hospital with incident HFrEF in 2004, only 1263 (4%) were clinically suspected of having SDB, only 553 (2%) were tested for SDB, and only 545 (2%) received treatment for SDB. 52 This indicates either that: (i) awareness of SDB in general and OSA in particular as a complicating factor in HFrEF is low, (ii) because patients with HFrEF and OSA lack excessive daytime sleepiness, the usual cardinal feature of OSA, OSA is not suspected, or (iii) because of an absence of large-scale randomized trial evidence that treating OSA in HFrEF patients reduces CV morbidity and mortality, physicians do not consider it important to diagnose and treat OSA in such patients. Whatever the case, these data make it clear that large-scale randomized trials designed to assess whether treating OSA in HFrEF patients will reduce morbidity and mortality are necessary to inform decisions about the value of screening HFrEF patients for OSA.
With respect to determining whether treating CSA in HFrEF patients will reduce morbidity and mortality, two multicentre randomized trials have attempted to address this issue. In the first, the CANPAP trial, 31 involving 258 patients followed for a mean of 2 years, treatment of CSA by CPAP had no effect on heart transplant-free survival, rate of hospital admissions, or quality of life. As a consequence the authors concluded that CPAP should not be used for routine therapy of CSA in patients with HFrEF.
In the second, the Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure (SERVE-HF) trial, 1325 HFrEF patients with an AHI of ≥15 and predominantly CSA were randomized to receive or not receive a proprietary ASV device (ResMed AutoSet CS). 53 To control CSA, this device uses minute volume of ventilation to trigger pressure support (i.e. minute ventilation-triggered ASV, or ASVmv) and has relatively high default pressures (minimum EPAP of 5 cmH 2 O and minimum inspiratory pressure support of 3 cmH 2 O). In the intention-to-treat analysis, ASVmv suppressed CSA, but there was no difference in the primary endpoint between those allocated to ASVmv and those not. However, risk of two secondary endpoints, all-cause and CV mortality, were increased in those randomized to ASVmv.
There were, however, several concerns about that trial including poor adherence to the study protocol, high crossover rates from the control to ASVmv arm and vice versa, and relatively high default inspiratory and expiratory pressures. These high pressures are more likely to lower cardiac output due to impedance of venous return, and to induce hyperventilation, alkalosis and hypokalaemia 54, 55 than the ASVpf device employed in ADVENT-HF with lower default pressures. 35 In addition, unlike the ASVmv device used in SERVE-HF, the ASVpf device used in this trial has an automatic algorithm to titrate EPAP to alleviate obstructive events. The ADVENT-HF trial is therefore uniquely positioned to determine: (i) whether the results of SERVE-HF were specific to their study device or were a class effect, 56 and (ii) whether ASV therapy can benefit HFrEF patients with OSA who do not have subjective daytime sleepiness.
Given these issues, the negative results of the SERVE-HF make it imperative that other trials of different ASV devices, such as ADVENT-HF are completed, to determine whether the results of SERVE-HF were specific to their study device or were a class effect. 56 It will also be important to determine whether ASVpf therapy can benefit patients with HFrEF and OSA who were not included in the SERVE-HF trial. Another important consideration that has been incorporated into the trial is close monitoring to ensure participant safety. The DSMC has reviewed the trial outcomes data three times since the results of the SERVE-HF were published, have not identified any safety concerns for subjects with either OSA or CSA, and have on all occasions recommended that the trial be continued as per protocol.
Conclusion
The ADVENT-HF trial is designed with sufficient power to resolve several of the important clinical issues discussed above. In particular, it will provide novel data on whether treating OSA by ASV in non-sleepy patients with HFrEF will reduce morbidity and mortality and improve health-related quality of life. Moreover, the information obtained from ADVENT-HF will provide insights into whether the increased rates of the secondary outcomes (i.e. all-cause and CV mortality) in HFrEF patients with CSA randomized to ASV in the SERVE-HF trial were specific to the device employed in that trial or are a more general consequence of treating CSA when present in advanced HFrEF. The trial will also yield important information on adherence to ASV therapy using an ASVpf algorithm as opposed to an ASVmv algorithm. Furthermore, the performance of full PSG in all subjects with centralized scoring and interpretation, use of an ASV device with lower default EPAP and pressure support levels, preferential use of nasal interface rather than a full face interface, as well as central interpretation of ASV titrations and prescription of ASV settings, will likely increase fidelity to the planned study intervention, and will also likely improve adherence to the study intervention. In this way, ADVENT-HF will contribute importantly to our understanding of the management of SDB in patients with HF. 
